Understanding how a body processes a therapy and a therapy’s effect on the body is a critical step for understanding safety and efficacy to support clinical trials. But the process of characterization differs between small-molecule therapies and biotherapeutics. Associate Director of Early Scientific Engagement at Labcorp Drug Development, Robert Nelson, …
Non-GLP sample analysis for ocular biodistribution studies
Traditional bioanalytical service providers are geared toward analyzing large sets of samples under various regulatory guidelines, such as large nonclinical and clinical studies, which are heavily regulated. This puts a heavy burden on these service providers, creating long lead times, resource constraints and lack of flexibility. Currently, many bioanalytical laboratories …
Welcome to the digital future of pathology
Imagine getting a phone call in the middle of your study from a scientist who is seeing something completely unexpected in your study results. You need to make a decision on how to move forward and you need to do it quickly. You don’t have time to wait for a …
Cell & Gene Therapy Answers: Preclinical oncology
Your source for answers on how to assess the preclinical efficacy of cell therapies. Watch the video > As the landscape of cell therapy continues to evolve, so are the tools to assess the efficacy of cell therapy in the preclinical space. To better understand Labcorp’s preclinical oncology role in …
Advancing inhalation toxicology capabilities to support chemical testing
Respiratory exposure to chemicals or agrochemicals poses potential risk to human health, especially to workers handling these products. Whether preparing a solution, dusting or spraying crops, or cleaning equipment, opportunities for inadvertent inhalation is a risk that can potentially lead to toxic effects, both acute and chronic. That’s why identifying …
Detecting measurable residual disease (MRD) in hematological malignancies using flow cytometry
A patient may be in complete remission during or after a cancer treatment, but a few cancer cells may persist in what is known as residual disease. To better inform prognoses, understand treatment decisions, predict a patient’s overall survival or understand the potential for disease relapse, it is important to …
Rare Disease Day 2022: Supporting patients, celebrating advancements
February 28 is Rare Disease Day, a day dear to the hearts of many at Labcorp. The day is observed to raise awareness and give support to the more than 300 million people worldwide living with rare diseases, as well as their family members and caretakers. At the heart of …
Optimizing success in application for US EPA registration of conventional new plant protection active substances under FIFRA
To open up the US crop protection market for an active substance you have already registered elsewhere, you will need to compare your existing data against the regulatory requirements of the US Environmental Protection Agency (EPA). In this blog, we outline the US regulatory landscape and suggest ways of optimizing …
TSCA and US state legislation: Navigating your chemical or agrochemical through the federal and state regulatory landscape in the USA
Registering your chemical or crop protection product with the US EPA under TSCA or FIFRA is the first and biggest step in its regulatory journey in the USA. But you will also need to navigate state-specific legislation and regulations, and for crop chemicals this includes registering in every state where …
Improving diagnostic efficiencies in histology with artificial intelligence and digital scoring
Digital analysis and artificial intelligence (AI) are not novel in anatomic pathology and histology, but the technology continues to evolve as it supports clinical trial enrollment as well as routine work in pathology. Paul Mesange, PhD, Principal Scientist, Histology, recently shared how Labcorp Drug Development (formerly known as Covance) has …